CDG Therapeutics, Inc. is a Chicago-based pharmaceutical (biotech) firm engaged in the development of proprietary peptides derived from pathogenic and nonpathogenic bacteria and green plants. These peptides possess a unique ability to preferentially enter cancer cells and induce cell cycle arrest and ultimately cell death.
The rare specificity and lack of toxicity suggest that CDG compounds may be effective in treating various types of cancer while reducing the significant adverse side effects associated with most existing cancer therapies. This new source of anticancer and potentially antiinfective agents has not been previously explored.
We have actively sought to protect our growing body of intellectual property and currently have 7 patents.
CDG's lead compound p28 entered Phase I clinical trial under Food and Drug Administration ("FDA") allowance in early 2009 (IND 77,754).
Corporate Offices:
CDG Therapeutics, Inc.
1317 Jackson Ave.
River Forest, IL 60305
708.771.5093
